Yan Dan, Earp H Shelton, DeRyckere Deborah, Graham Douglas K
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA.
UNC Lineberger Comprehensive Cancer Center, Department of Medicine, Chapel Hill, NC 27599, USA.
Cancers (Basel). 2021 Nov 11;13(22):5639. doi: 10.3390/cancers13225639.
MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug resistance, and disease progression in patients with NSCLC. The TAM receptors on host tumor infiltrating cells also play important roles in the immunosuppressive tumor microenvironment. Thus, MERTK and AXL are attractive biologic targets for NSCLC treatment. Here, we will review physiologic and oncologic roles for MERTK and AXL with an emphasis on the potential to target these kinases in NSCLCs with activating EGFR mutations.
MERTK和AXL是受体酪氨酸激酶TAM家族的成员，在非小细胞肺癌（NSCLC）中分别有69%和93%异常表达。MERTK和/或AXL的表达为NSCLC细胞提供了生存优势，并与NSCLC患者的淋巴结转移、耐药性和疾病进展相关。宿主肿瘤浸润细胞上的TAM受体在免疫抑制性肿瘤微环境中也发挥重要作用。因此，MERTK和AXL是NSCLC治疗中具有吸引力的生物学靶点。在此，我们将综述MERTK和AXL的生理和肿瘤学作用，重点关注在具有激活型EGFR突变的NSCLC中靶向这些激酶的潜力。
